BridgeMD
Tests treatment safety and results for HIV-1-infection
Official title Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
ClinicalTrials.gov ID: NCT06071767
What this study is testing
What is ChAdOx1.tHIVconsv1?
ChAdOx1.tHIVconsv1 is an investigational medicine, given as an injection into a muscle, being studied as a potential treatment for hiv-1-infection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Provision of written informed consent.
- History of Initiation of combination ART within 90 days of acute HIV diagnosis
- On ART for at least 12 months with no known ART interruption \>28 consecutive days within 12 months prior to Step 1 Study Entry
- ART with an integrase inhibitor-based regimen with two NRTIs or dolutegravir/lamivudine regimen for at least 6 weeks prior to Study Entry.
- Willingness to participate in the ATI and willingness to restart ART according to study guidelines.
You likely can't join if
- Currently pregnant or breastfeeding or planning to become pregnant during study participation.
- Prior receipt of anti-HIV broadly neutralizing antibody therapy.
- Receipt of any non-HIV monoclonal antibody therapy within 1 year prior to study entry.
- Prior receipt of a latency-reversing agent (LRA).
- Receipt of HIV-1 or other investigational vaccines within 6 months prior to Study Entry.
- Receipt of a live-virus vaccine within 60 days or any vaccination within 14 days prior to Study Entry.
See the full eligibility criteria
- Provision of written informed consent.
- History of Initiation of combination ART within 90 days of acute HIV diagnosis
- On ART for at least 12 months with no known ART interruption \>28 consecutive days within 12 months prior to Step 1 Study Entry
- ART with an integrase inhibitor-based regimen with two NRTIs or dolutegravir/lamivudine regimen for at least 6 weeks prior to Study Entry.
- Willingness to participate in the ATI and willingness to restart ART according to study guidelines.
- Willingness to adhere to protocol therapy and complete all study visits.
- Weight ≥50 kg and ≤150 kg at Screening.
- CD4 cell count ≥450 cells/mm3 obtained within 60 days prior to Study Entry.
- HIV-1 RNA \ 50 copies/mL) for at least 1 year and within 60 days prior to Study Entry.
- Select laboratory results within 60 days of study entry
- For cisgender women and transgender men of reproductive potential, negative urine or serum pregnancy test within 48 hours prior to or at study Entry.
- Participants who are able to become pregnant and who are engaging in sexual activity that could lead to pregnancy must agree to use two methods of contraception, one of which must be a highly effective methods for...
- Availability of results of HLA typing (required for randomization).
- Completion of pre-entry leukapheresis or LVBD.
- Currently pregnant or breastfeeding or planning to become pregnant during study participation.
- Prior receipt of anti-HIV broadly neutralizing antibody therapy.
- Receipt of any non-HIV monoclonal antibody therapy within 1 year prior to study entry.
- Prior receipt of a latency-reversing agent (LRA).
- Receipt of HIV-1 or other investigational vaccines within 6 months prior to Study Entry.
- Receipt of a live-virus vaccine within 60 days or any vaccination within 14 days prior to Study Entry.
- Receipt of any simian adenovirus-vectored vaccine (e.g., anti-COVID-19 AZD1222) within 12 months prior to Step 1 Study Entry.
- Known allergy/sensitivity or any hypersensitivity to components of study treatments or their formulations.
- Known severe chicken egg allergy.
- Known history of a severe reaction or anaphylaxis to prior vaccinations or antibody preparations (e.g., intravenous immunoglobulin).
- Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity).
- Any history of anaphylaxis and related symptoms such as hives, respiratory difficulty, or angioedema.
- Previous or current history of bleeding factor deficiency, coagulopathy or platelet disorder or on chronic anticoagulation.
- History of inflammatory neurologic diseases.
- History of pregnancy, head trauma or major surgery within 90 days prior to Step 1 Study Entry.
- History of use of any immunomodulatory medications within the 6 months prior to Step 1 Study Entry.
- Significant serious skin disease, such as but not limited to active rash, eczema, psoriasis, or urticaria.
- Autoimmune disease (e.g., lupus, multiple sclerosis, and others) requiring ongoing immunosuppression.
- Known history of CDC Stage 3 opportunistic infection (OI).
- Any history of an HIV-associated malignancy.
- Known or suspected active or untreated latent Mycobacterium tuberculosis infection.
- Active or recent non-HIV-associated malignancy.
- Serious illness requiring systemic treatment and/or hospitalization within 90 days prior to study entry.
- Known resistance to one or more drugs in two or more ARV drug classes.
- History of or current clinical atherosclerotic cardiovascular disease
- Current advanced liver disease.
- Use of complementary or alternative medicines within 14 days prior study entry.
The study team makes the final eligibility decision.
Where it's taking place
- San Diego, California, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Boston, Massachusetts, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Chapel Hill, North Carolina, United States
- Columbus, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Houston, Texas, United States
- Porto Alegre, Rio Grande do Sul, Brazil
- Rio de Janeiro, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Diego, California, United States; Atlanta, Georgia, United States; Chicago, Illinois, United States; Boston, Massachusetts, United States; St Louis, Missouri, United States; New York, New York, United States and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.